LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS

1 . A compound of formula:

including any pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 .

3 . A pharmaceutical composition comprising the compound of claim 1 in a formulation comprising liposomes.

4 . The pharmaceutical composition of claim 2 , further comprising an antigen.

5 . The pharmaceutical composition of claim 4 , wherein the compound and antigen are admixed into a single composition.

6 . The pharmaceutical composition of claim 4 , wherein the compound and antigen are present in separate components of the composition to be administered in combination.

7 . The pharmaceutical composition of any one of claim 4 wherein the antigen is a cancer vaccine.

8 . The pharmaceutical composition of any one of claim 4 wherein the antigen is a viral vaccine.

9 . A method of enhancing the effectiveness of a vaccine antigen by administering as a vaccine adjuvant the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

10 . The method of claim 9 , wherein the compound is incorporated into a liposome formulation.

11 . A method of treating a neoplastic disease, the method comprising administering the compound N-(4-{[4-amino-2-butyl-1H-imidazo [4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof, to a human or animal having the neoplastic disease.

12 . The method of claim 11 , wherein the compound is in a liposome formulation.

13 . The method of claim 12 , wherein the formulation is administered directly into a localized tumor mass.

14 . The method of any one of claim 11 , further including administration of a cancer vaccine antigen.